This podcast is the first of a series of three recordings of the Lymphoma Special Interest Group (SIG) Education Session at the 2025 BSH Annual Scientific Meeting.  The Lymphoma SIG is delighted to share talks from three great speakers with the wider audience.   In this recording, Dr David Lewis discusses first-line treatment for mantle cell lymphoma in 2025, focusing on three main themes: 1) the emerging use of Bruton’s tyrosine kinase inhibitors (BTKis) in first-line treatment, 2) the role of autologous stem cell transplant, and 3) the clinical utility of minimal residual disease (MRD).   Dr David Lewis is a Consultant Haematologist at the University Hospitals Plymouth and an Honorary Associate Professor at the University of Plymouth.  He is the Chief Investigator of the ENRICH trial – a randomised, open-label study of Rituximab/Ibrutinib versus. Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma.